ClinicalTrials.gg
CompletedNCT02171624Updated Jun 24, 2014

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

A Phase 1 interventional study of dabigatran etexilate and quinidine in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Open-label, two-way crossover design with a quinidine sulfate run-in period followed by a randomised sequence of dabigatran etexilate plus quinidine sulfate or dabigatran etexilate alone to evaluate the safety of co-administration of dabigatran etexilate and quinidine. and the pharmacokinetic interaction between quinidine and dabigatran etexilate.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects
  • Age ≥18 and Age ≤55 years
  • (BMI) ≥18.5 and BMI \<30 kg/m2
  • Signed and dated written prior to admission to the study in accordance with GCP and the local legislation.

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including Blood Pressure (BP), Pulse Rate (PR) and (ECG)) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial or that prolong the /QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within thirty days prior to administration or during the trial
  • Inability to refrain from smoking on trial days Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
  • A history of additional risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Taking drugs which are known P-gp and/or inhibitors or inducers (verapamil, phenothiazine antipsychotics, macrolide antibiotics (clarithromycin, erythromycin), antifungal drugs, antiviral drugs (protease inhibitors like nelfinavir) or St. John´s Wort) within the last 4 weeks before screening
  • Taking drugs which are known CYP2D6 substrates (antidepressants, antiarrhythmics, beta blockers) within the last 2 weeks before screening
  • For female subjects:

    • Pregnancy or planning to become pregnant within 2 months of study completion
    • Positive pregnancy test
    • No adequate e.g., sterilisation, IUD (intrauterine device), have not been using a barrier method of contraception for at least 3 months prior to participation in the study
    • Are not willing or are unable to use a reliable method of barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during and up to 2 months after completion/termination of the trial
    • Chronic use of oral contraception or hormone replacement containing ethinyl estradiol as the only method of contraception
    • Partner is unwilling to use condoms
    • Currently lactating
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    dabigatran etexilate

    quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order

    Drug: dabigatran etexilate · Drug: quinidine

  • Experimental
    quinidine

    quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order

    Drug: dabigatran etexilate · Drug: quinidine

Interventions

06

What researchers measure

Primary outcomes

  1. Differences between treatments in systolic blood pressure profiles (using area under the BP-time curve)

    Time frame: -0:15 before, and every 15 minutes for 2 hours post-dose, 3, 4 and 12 hours post dose

  2. Incidence of symptomatic hypotension

    Time frame: -0:15 before, and every 15 minutes for 2 hours post-dose, 3, 4 and 12 hours post dose

Secondary outcomes

  1. Area under the effect curve (AUEC) for activated partial thromboplastin time (aPTT), thrombin time (TT) and ecarin clotting time (ECT)

    Time frame: up to 48 hours after last dose

  2. Maximum effect ratio (ERmax) for activated partial thromboplastin time (aPTT), thrombin time (TT) and ecarin clotting time (ECT)

    Time frame: up to 48 hours after last dose

  3. Occurrence of Adverse Events

    Time frame: up to day 26

  4. Abnormal findings in physical examination

    Time frame: up to day 26

  5. Changes from baseline in Vital Signs (Blood Pressure (BP), Heart Rate (HR))

    Time frame: up to day 26

  6. Changes from baseline in 12-lead ECG (electrocardiogram)

    Time frame: up to day 26

  7. Changes from baseline in QT prolongation

    Time frame: up to day 26

  8. Changes in clinical laboratory tests

    Time frame: up to day 26

  9. Number of patients with adverse events leading to treatment discontinuation

    Time frame: up to day 26

  10. AUC (area under the concentration-time curve of the analyte in plasma)

    Time frame: up to 48 hours after the last dose

  11. Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: up to 48 hours after the last dose

  12. tmax (time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 48 hours after the last dose

  13. λz (terminal rate constant in plasma)

    Time frame: up to 48 hours after the last dose

  14. t½ (terminal half-life of the analyte in plasma)

    Time frame: up to 48 hours after the last dose

  15. Cpre (pre-dose concentration of the analyte in plasma immediately before administration of the following dose)

    Time frame: up to 48 hours after the last dose

  16. MRTpo,ss (mean residence time of the analyte in the body at steady state after po administration)

    Time frame: up to 48 hours after last dose

  17. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular dose)

    Time frame: up to 48 hours after last dose

  18. CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular administration)

    Time frame: up to 48 hours after last dose

  19. Cavg (average concentration of the analyte in plasma under steady-state conditions)

    Time frame: up to 48 hours after last dose

  20. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state)

    Time frame: up to 48 hours after last dose

  21. PTF (peak trough fluctuation)

    Time frame: up to 48 hours after last administration

  22. RAUCt1-t2, MET, 5 (ratio of AUCt1-t2 of 3-OH-quinidine/quinidine)

    Time frame: up to 48 hours after last dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Mar 2009
Primary completionActual
Apr 2009
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171624
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Mar 2009
Primary completion
Apr 2009
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Quinidine

Start the discussion